Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | PRKCG | P05129 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCH | P24723 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828232 | 0.78 | POLB (1.00) | ALDH1A1POLBHPGDRXFP1PSMB8 | |
| SCHEMBL13599975 | 0.78 | ALDH1A1 (1.00) | ALDH1A1POLBHPGDRXFP1PSMB8 | |
| SCHEMBL30838374 | 0.78 | POLB (1.00) | ALDH1A1POLBHPGDRXFP1PSMB8 | |
| SCHEMBL23241285 | 0.78 | HCRTR2 (0.47) | ALDH1A1POLBHPGD | |
| SCHEMBL31236070 | 0.76 | POLB (0.69) | ALDH1A1POLBHPGDRXFP1PSMB8 | |
| SCHEMBL7282502 | 0.76 | POLB (0.69) | ALDH1A1POLBHPGDRXFP1PSMB8 | |
| SCHEMBL2496853 | 0.75 | RXFP1 (0.59) | ALDH1A1POLBHPGDRXFP1PSMB8 | |
| SCHEMBL3931216 | 0.72 | POLB (0.40) | ALDH1A1POLBHPGDRXFP1PSMB8 | |
| SCHEMBL22541954 | 0.72 | TP53 (0.49) | ALDH1A1POLBHPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL23241300 | 0.71 | HCRTR2 (0.51) | ALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822134-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-11-21 | — | — | US | disclosed |
| US-9822134-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-11-21 | — | — | US | disclosed |
| US-9556210-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-01-31 | — | — | US | disclosed |
| US-9556210-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-01-31 | — | — | US | disclosed |
| US-20160176903-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SABAG-RFA LTD. (IL) | 2016-06-23 | — | — | US | disclosed |
| US-20160039850-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SABAG-RFA LTD. (IL) | 2016-02-11 | — | — | US | disclosed |
| US-9156865-B2 | System for delivering therapeutic agents into living cells and cells nuclei | DELIVERSIR LTD (IL) | 2015-10-13 | — | — | US | disclosed |
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | disclosed |
| US-20130137755-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SEGEV LABORATORIES LIMITED (IL) | 2013-05-30 | — | — | US | disclosed |
| US-8309514-B2 | Peptide nucleic acid based guanidinium compounds | NITTO DENKO CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070082906-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-04-12 | — | — | US | disclosed |
| US-20070078094-A1 | Guanidinium delivery carriers | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| WO-2007038172-A2 | GUANIDINIUM CARRIERS | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078078-A1 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | NITTO DENKO CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149536-A1 | Inhibitors of Akt activity | AKT1, AKT2, AKT3 | ALDH1A1 3399/4885POLB 2450/4885HPGD 2877/4885 |
| US-20160039850-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | ALDH1A1 4566/4885POLB 1951/4885HPGD 4078/4885 |
| US-20130137755-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | ALDH1A1 4566/4885POLB 1951/4885HPGD 4078/4885 |
| US-20070078094-A1 | Guanidinium delivery carriers | SLC2A9, SLC29A2, SLC2A4 | ALDH1A1 1632/4885POLB 3086/4885HPGD 2730/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | ALDH1A1 3618/4885POLB 1872/4885HPGD 3673/4885 |
| US-20070072802-A1 | Peptide nucleic acid based guanidinium compounds | SLC29A1, SLC29A2, SLC28A1 | ALDH1A1 4108/4885POLB 344/4885HPGD 3720/4885 |
| US-20070082906-A1 | Inhibitors of akt activity | AKT2, AKT1, AKT3 | ALDH1A1 3625/4885POLB 2859/4885HPGD 3348/4885 |
| US-20070078078-A1 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | GLS, FABP2, GOLIM4 | ALDH1A1 3594/4885POLB 3105/4885HPGD 4139/4885 |
| US-20160176903-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | ALDH1A1 4566/4885POLB 1951/4885HPGD 4078/4885 |
| US-20070142388-A1 | Inhibitors of Akt activity | AKT2, AKT1, AKT3 | ALDH1A1 3425/4885POLB 2331/4885HPGD 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.